Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J A Hank

Showing results (41-50 of 96) with videos related to

Pageof 10
Sort By:
Progress in Clinical and Biological Research|January 1, 1987
Overview: cellular immunotherapy of cancerP M Sondel, J A Hank, B P Chen, et al.
Progress in Clinical and Biological Research|January 1, 1987
Phase 1 clinical evaluation of recombinant interleukin-2P C Kohler, J A Hank, K H Moore, et al.
Journal of Biological Response Modifiers|February 1, 1990
Depressed in vitro T cell responses concomitant with augmented interleukin-2 responses by lymphocytes from cancer patients following in vivo treatment with interleukin-2J A Hank, J A Sosman, P C Kohler, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1989
Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activationS D Voss, J A Hank, C A Nobis, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|August 1, 1991
Activation of human T cells obtained pre- and post-interleukin-2 (IL-2) therapy by anti-CD3 monoclonal antibody plus IL-2: implications for combined in vivo treatmentG Weil-Hillman, K Schell, D M Segal, et al.
The Journal of Allergy and Clinical Immunology|March 1, 1990
The appearance of hypodense eosinophils during interleukin-2 treatmentJ B Sedgwick, W E Frick, P M Sondel, et al.
Blood|May 15, 1990
Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cellsJ A Sosman, K R Oettel, S D Smith, et al.
Critical Reviews in Oncology/Hematology|January 1, 1989
The cellular immunotherapy of cancer: current and potential uses of interleukin-2P M Sondel, J A Hank, P C Kohler, et al.
Cancer|February 1, 1985
Clinical response of a patient with diffuse histiocytic lymphoma to adoptive chemoimmunotherapy using cyclophosphamide and alloactivated haploidentical lymphocytes. A case report and phase I trialP C Kohler, J A Hank, R Exten, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 1, 1990
Human T cell receptor-gamma delta-expressing T-cell lines recognize MHC-controlled elements on autologous EBV-LCL that are not HLA-A, -B, -C, -DR, -DQ, or -DPV Lam, R DeMars, B P Chen, et al.
Pageof 10

Showing results (41-50 of 96) with videos related to

Sort By:
Pageof 10
Progress in Clinical and Biological Research|January 1, 1987
Overview: cellular immunotherapy of cancerP M Sondel, J A Hank, B P Chen, et al.
Progress in Clinical and Biological Research|January 1, 1987
Phase 1 clinical evaluation of recombinant interleukin-2P C Kohler, J A Hank, K H Moore, et al.
Journal of Biological Response Modifiers|February 1, 1990
Depressed in vitro T cell responses concomitant with augmented interleukin-2 responses by lymphocytes from cancer patients following in vivo treatment with interleukin-2J A Hank, J A Sosman, P C Kohler, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1989
Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activationS D Voss, J A Hank, C A Nobis, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|August 1, 1991
Activation of human T cells obtained pre- and post-interleukin-2 (IL-2) therapy by anti-CD3 monoclonal antibody plus IL-2: implications for combined in vivo treatmentG Weil-Hillman, K Schell, D M Segal, et al.
The Journal of Allergy and Clinical Immunology|March 1, 1990
The appearance of hypodense eosinophils during interleukin-2 treatmentJ B Sedgwick, W E Frick, P M Sondel, et al.
Blood|May 15, 1990
Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cellsJ A Sosman, K R Oettel, S D Smith, et al.
Critical Reviews in Oncology/Hematology|January 1, 1989
The cellular immunotherapy of cancer: current and potential uses of interleukin-2P M Sondel, J A Hank, P C Kohler, et al.
Cancer|February 1, 1985
Clinical response of a patient with diffuse histiocytic lymphoma to adoptive chemoimmunotherapy using cyclophosphamide and alloactivated haploidentical lymphocytes. A case report and phase I trialP C Kohler, J A Hank, R Exten, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 1, 1990
Human T cell receptor-gamma delta-expressing T-cell lines recognize MHC-controlled elements on autologous EBV-LCL that are not HLA-A, -B, -C, -DR, -DQ, or -DPV Lam, R DeMars, B P Chen, et al.
Pageof 10